Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Brain Neoplasms × alectinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 2 Thyroid Neoplasms 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1

Interventions

Temozolomide 24 Radiosurgery 12 Bevacizumab 12 Radiotherapy 8 Carboplatin 8 pembrolizumab 7 Trastuzumab 6 Erlotinib Hydrochloride 5 abemaciclib 4 Paclitaxel 4 Irinotecan 4 Capecitabine 4 tipifarnib 3 temsirolimus 3 Sirolimus 3 Radiation 3 Mental Status and Dementia Tests 3 Ipilimumab 3 Everolimus 3 Aminolevulinic Acid 3 tucatinib 2 pertuzumab 2 fludarabine 2 durvalumab 2 alovudine 2 Vorinostat 2 Surgical Procedures, Operative 2 Sorafenib 2 Nivolumab 2 NVP-BKM120 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05987644 2026-03-09

DURABLE

Hoosier Cancer Research Network

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡